Immunotherapy for osteosarcoma: Where do we go from here?-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Immunotherapy for osteosarcoma: Where do we go from here?

Published:2018-06-19 Issue:9 Volume:65 Page:e27227
ISSN:1545-5009
Container-title:Pediatric Blood & Cancer
language:en
Short-container-title:Pediatr Blood Cancer

Author:

Wedekind Mary F.¹²^ORCID,Wagner Lars M.³^ORCID,Cripe Timothy P.¹²^ORCID

Affiliation:

1. Division of Hematology, Oncology, and Blood and Marrow Transplant; Department of Pediatrics; Nationwide Children's Hospital; Columbus Ohio

2. Center for Childhood Cancer and Blood Diseases; The Research Institute at Nationwide Children's Hospital; Columbus Ohio

3. Division of Hematology-Oncology; Department of Pediatrics; Kentucky Children's Hospital; Lexington Kentucky

Publisher

Wiley

Subject

Oncology,Hematology,Pediatrics, Perinatology and Child Health

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/pbc.27227/fullpdf

Reference89 articles.

1. Osteosarcoma treatment-where do we stand? A state of the art review;Luetke;Cancer Treat Rev,2014

2. Expression and clinical association of programmed cell death-1, programmed death-ligand-1 and CD8(+) lymphocytes in primary sarcomas is subtype dependent;Erp;Oncotarget,2017

3. CD163-positive tumor-associated macrophages and CD8-positive cytotoxic lymphocytes are powerful diagnostic markers for the therapeutic stratification of osteosarcoma patients: an immunohistochemical analysis of the biopsies fromthe French OS2006 phase 3 trial;Gomez-Brouchet;Oncoimmunology,2017

4. Immune infiltration and PD-L1 expression in the tumor microenvironment are prognostic in osteosarcoma;Koirala;Sci Rep,2016

5. Translational biology of osteosarcoma;Kansara;Nat Rev Cancer,2014

Cited by 119 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A useful mTORC1 signaling-related RiskScore model for the personalized treatment of osteosarcoma patients by using the bulk RNA-seq analysis;Discover Oncology;2024-09-09

2. Combination of Sintilimab and Anlotinib for Metastatic Osteosarcoma: A Case Report;OncoTargets and Therapy;2024-08

3. KAT7 serves as an oncogenic gene and regulates CCL3 expression via STAT1 signaling in osteosarcoma;Biochemical and Biophysical Research Communications;2024-08

4. Identification and validation of disulfidptosis-related signature to evaluate clinical outcomes, immune infiltration and drug sensitivity in osteosarcoma;2024-06-12

5. Advancements in osteosarcoma management: integrating immune microenvironment insights with immunotherapeutic strategies;Frontiers in Cell and Developmental Biology;2024-06-10

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3